Microcap Ledger Sera Prognostics, Inc. $SERA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Services-Medical Laboratories
- Headquarters
- Salt Lake City, UT
- Fiscal year end
- December 31
What the company doesAI summary of filing
Sera Prognostics is a women's health company that develops blood-based biomarker tests to predict pregnancy complications. The company's lead product, the PreTRM test, is a non-invasive blood test administered during weeks 18–20 of pregnancy that predicts a woman's risk of spontaneous preterm birth. The PreTRM test is commercially available and generates revenue through third-party reimbursement from health insurance payers, integrated health systems, and other payment models, with a CPT code priced by CMS at $750. The company is developing a pipeline of additional biomarker tests for other pregnancy-related conditions such as preeclampsia and gestational diabetes using its proprietary proteomics and bioinformatics platform. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $44.0K | −$17.54M | −$15.09M | $4.40M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $81.0K | −$31.93M | −$25.62M | $3.94M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $77.0K | −$32.90M | −$14.19M | $4.04M | [10-K 2026-03-18] |
- Quarterly cash burn
- −$7.54M
- Cash runway Estimate
- ~1.7 months
Capital structure and dilution
- Shelf registration
- S-3 filed 2024-08-07; declared effective 2024-08-13 [S-3 2024-08-07]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-10 | Anderson Dyaarl Lee Jr. | sell | 1,800 | $2.00 | [4 2026-09-11] |
| 2026-09-10 | Lindgardt Zhenya | sell | 7,022 | $2.00 | [4 2026-09-11] |
| 2026-09-10 | Inglis Tiffany Eul Davis | sell | 486 | $2.00 | [4 2026-09-11] |
| 2026-09-10 | Jackson Benjamin | sell | 2,190 | $2.00 | [4 2026-09-11] |
| 2026-09-08 | Lindgardt Zhenya | sell | 20,139 | $2.00 | [4 2026-09-09] |
| 2026-08-31 | Gleason Scott | grant | 117,924 | — | [4 2026-09-01] |
| 2026-07-10 | Phillips Joshua | grant | 22,426 | — | [4 2026-07-14] |
| 2026-07-10 | Phillips Joshua | grant | 2,260 | — | [4 2026-07-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-19 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations |
| 2026-07-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-30 | 8-K | Director or officer change |
| 2026-06-04 | 8-K | Shareholder vote results |
| 2026-06-01 | 8-K | Director or officer change |
| 2026-05-06 | 10-Q | Quarterly report |
| 2026-05-06 | 8-K | Results of operations |
| 2026-05-01 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-24 | DEF 14A | Proxy statement |
| 2026-03-18 | 424B5 | Prospectus or prospectus supplement |
Alerts for $SERA
Email me when Sera Prognostics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.